You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Strep-CaDI: A fast, accurate, and sensitive point-of-care test for Group A Streptococcus

    SBC: BURST DIAGNOSTICS INC            Topic: NIAID

    SUMMARY The current rapid antigen detection tests for group A strep lack sensitivity and result in upwards of 10 million unnecessary antibiotic treatments provided to children each year. Current diagnostic methods utilized when a patient presents at a clinic with a sore throat include a throat swab and rapid strep test. A positive rapid test results in antibiotic prescription, but due to the low s ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease

    SBC: CRESTONE, INC.            Topic: NIAID

    ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HSCT) is an effective therapy for a number of malignant and non- malignant blood and metabolic diseases, but its applicability has been limited by graft-versus-host disease (GvHD). GvHD is responsible for 15-30% of deaths that occur following HSCT and is the main cause of morbidity in up to 50% of recipients. Current prevention and treat ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Beat Extreme: An Interactive, Tailored Text Messaging Program Combining Extreme Weather Alerts with Hyper-localized Resources and Actionable Insights for Addressing Climate Change

    SBC: Pro-Change Behavior Systems, Inc.            Topic: R

    Summary Climate change is an urgent public health threat, and climate-related health risks disproportionately impact vulnerable populations. Public health agencies have underscored the need to develop scalable and innovative health-equity centered, multi-level interventions that offer tools and resources to 1) raise awareness of the inextricable link between climate change and health and 2) suppor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Filtration Media for In-Home PFAS Removal from Drinking Water

    SBC: TDA RESEARCH, INC.            Topic: NIEHS

    Project Summary/Abstract Title Filtration Media for In-Home PFAS Removal from Drinking Water SBIR Phase II Application P.I.: Steven Dietz, TDA Research, Inc. Per- and polyfluoroalkyl substances (PFAS), also commonly known as perfluorinated compounds, are a large family of man-made, globally distributed chemicals that have been used for decades. Perfluorooctanoic acid (PFOA) and perfluorooctane sul ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. VDX-111: A novel targeted therapeutic for triple-negative breast cancer

    SBC: VONA THERAPEUTICS LLC            Topic: 102

    PROJECT SUMMARY Triple-negative breast cancers (TNBC) represent a significant challenge to basic scientists studying themolecular underpinnings of the disease and to patients and clinicians who deal directly with this most deadly andtherapy-resistant of breast cancers. Presently, targeted approaches toward the treatment of TNBC are lacking.This project directly addresses this critical unmet need. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Machine Learning Phenotypic De Novo Drug Design

    SBC: PGI HOLDING CORPORATION            Topic: 101

    PROJECT SUMMARY The high rate of failure in CNS drug discovery, in particular of the first-in-class therapeutics with new modes of action, highlights a clear unmet need to improve the success rate in drug discovery for psychiatric disorders. One well-known issue is the poor ability of current bioassays and animal models to predict the efficacy and side- effects of compounds. Another important issu ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an AI-empowered device that utilizes multimodal data-visualization to aid in the diagnosis, and treatment, of OUD

    SBC: WAVi Co.            Topic: NIDA

    Abstract Assessing the effectiveness of opioid use disorder (OUD), where high relapse rates create financial and social tolls, is a pressing clinical problem in need of better measurement tools. The ability to identify cognitive changes should improve outcomes but current intake into rehabilitation programs doesn’t typically include cognitive tests. Simple, quick, cost-effective, and objective m ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Substance Use Disorder Artificially Intelligent chatbot for screening, assessment and referral: SUD Bot

    SBC: Clinic Chat LLC            Topic: NIDA

    ABSTRACT The opioid epidemic is considered one of the most severe public health crises we are facing in the U.S. and is worsened by use of stimulants such as methamphetamine. The US Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use accompanied by offers of and referrals to services that include accurate diagnosis, effective treatment and appropriate care of a subs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. New 5HT2AR Target Identification and Assay Development for Discovering Psychoplastogenic Compounds

    SBC: BIOINVENU CORPORATION            Topic: NIDA

    Specific Aim: New 5HT2AR/14-3-3 isoform signal pathway identification and assay development for discovering psychoplastogenic compounds. Significance: Emerging data and limited clinical results show the promise of psychedelic drugs in the durable relief of people from seemingly untreatable psychiatric disorders and drug addictions. Neuroimaging evidence supports the concept that the brain after a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. ADA2 Diagnostic Platform: Point-of-care test for determination of patient enzyme levels for diagnosis of the rare disease Deaminase2 Deficiency (DADA2)

    SBC: ANALYTICAL DIAGNOSTIC SOLUTIONS INC            Topic: NIAID

    Abstract This application is in regard to the National Center for Advancing Translational Sciences SBIR/STTR Omnibus Solicitation (Research Priority: Tools and technologies that address the rapid diagnosis and/or clinical management of rare diseases). In Vitro Diagnostic Solutions, LLC (IVDS) proposes to develop a point-of-care (POC) blood test to rapidly determine patient enzyme levels for the di ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government